Imigran (Sumatriptan)

Imigran (sumatriptan) acts within the migraine therapeutic pathway to provide acute headache relief.

• Migraine: rapid alleviation of migraine headache, nausea, photophobia, and phonophobia in adult patients.
• Migraine with aura: effective reduction of headache and associated aura symptoms when administered early in an attack.
• Cluster headache: acute termination of cluster headache attacks in patients responsive to triptan therapy.
• Migraine in patients with contraindications to NSAIDs: provides an alternative acute therapy when NSAIDs are unsuitable.
• Severe migraine unresponsive to oral triptans: subcutaneous sumatriptan offers faster absorption and relief.

• Sumatriptan binds selectively to 5‑HT1B and 5‑HT1D receptors on intracranial blood vessels and trigeminal nerve endings. Activation of 5‑HT1B receptors causes cranial vasoconstriction, while 5‑HT1D stimulation inhibits release of pro‑inflammatory neuropeptides such as CGRP. Together these actions reduce vascular dilation and neurogenic inflammation, aborting the migraine cascade and relieving headache pain. The drug’s high affinity for these receptors allows rapid onset of effect after subcutaneous administration.

Sumatriptan may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Injection site pain: mild to moderate discomfort at the injection site.
• Tingling or numbness: transient paresthesia in the face or extremities.
• Warmth or flushing: sensation of heat or redness.
• Nausea: mild gastrointestinal upset.
• Dizziness: light‑headed feeling.
• Fatigue: temporary tiredness.

Serious or Rare Side Effects

• Chest pain or tightness: possible cardiac ischemia.
• Coronary vasospasm: reduced blood flow to the heart.
• Serotonin syndrome: agitation, hyperthermia, tremor when combined with serotonergic drugs.
• Severe allergic reaction: rash, swelling, difficulty breathing.
• Hypertension: sudden increase in blood pressure.
• Stroke or transient ischemic attack: rare cerebrovascular events.

Before using Imigran, consider the following precautions to ensure safe administration.

• Cardiovascular assessment: avoid use in patients with uncontrolled coronary artery disease or recent myocardial infarction.
• Medication history: review concomitant serotonergic agents to reduce risk of serotonin syndrome.
• Pregnancy: prescribe only if potential benefit justifies potential risk to the fetus.
• Renal or hepatic impairment: use with caution in severe organ dysfunction, as clearance may be altered.
• Age restrictions: safety and efficacy have not been established in children or adolescents.
• Store at ambient temperature: keep in original packaging, protect from moisture and light.

Sumatriptan can interact with several drug classes; awareness of major and moderate interactions helps prevent adverse events.

Major Interactions (Avoid)

• MAO inhibitors: combined use may precipitate severe serotonin syndrome.
• SSRIs, SNRIs, or other serotonergic antidepressants: increase risk of serotonin toxicity.
• Ergot alkaloids: concurrent use can cause excessive vasoconstriction.
• Other triptans: additive vasoconstrictive effects may lead to cardiovascular complications.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may elevate plasma levels of sumatriptan, requiring observation.
• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can increase exposure and side‑effect potential.